Gİrgİn Birkan, KaradaĞ-Alpaslan Medine, KocabaŞ Fatih
Regenerative Biology Research Laboratory, Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul Turkey.
Graduate School of Natural and Applied Sciences, Yeditepe University, İstanbul Turkey.
Turk J Biol. 2020 Dec 14;44(6):328-355. doi: 10.3906/biy-2006-25. eCollection 2020.
MEIS proteins are historically associated with tumorigenesis, metastasis, and invasion in cancer. MEIS and associated PBX-HOX proteins may act as tumor suppressors or oncogenes in different cellular settings. Their expressions tend to be misregulated in various cancers. Bioinformatic analyses have suggested their upregulation in leukemia/lymphoma, thymoma, pancreas, glioma, and glioblastoma, and downregulation in cervical, uterine, rectum, and colon cancers. However, every cancer type includes, at least, a subtype with high MEIS expression. In addition, studies have highlighted that MEIS proteins and associated factors may function as diagnostic or therapeutic biomarkers for various diseases. Herein, MEIS proteins and associated factors in tumorigenesis are discussed with recent discoveries in addition to how they could be modulated by noncoding RNAs or newly developed small-molecule MEIS inhibitors.
MEIS蛋白在历史上与癌症的肿瘤发生、转移和侵袭相关。MEIS及相关的PBX-HOX蛋白在不同的细胞环境中可能充当肿瘤抑制因子或致癌基因。它们的表达在各种癌症中往往失调。生物信息学分析表明,它们在白血病/淋巴瘤、胸腺瘤、胰腺、神经胶质瘤和胶质母细胞瘤中上调,而在宫颈癌、子宫癌、直肠癌和结肠癌中下调。然而,每种癌症类型至少包括一个MEIS高表达的亚型。此外,研究强调MEIS蛋白及相关因子可能作为各种疾病的诊断或治疗生物标志物。本文除了讨论MEIS蛋白及相关因子如何被非编码RNA或新开发的小分子MEIS抑制剂调节外,还结合最新发现探讨了它们在肿瘤发生中的作用。